Skip to main content
Article
TRAIL is a novel antiviral protein against dengue virus
Open Access Articles
  • Rajas V. Warke
  • Katherine J. Martin
  • Krisanthi Giaya, University of Massachusetts Medical School
  • Sunil K. Shaw
  • Alan L. Rothman, University of Massachusetts Medical School
  • Irene Bosch, University of Massachusetts Medical School
UMMS Affiliation
Center for Infectious Disease and Vaccine Research; Department of Medicine, Division of Infectious Diseases and Immunology
Date
10-5-2007
Document Type
Article
Subjects
B-Lymphocytes; Cell Line; Cells, Cultured; Dendritic Cells; Dengue Virus; Endothelial Cells; Gene Expression Profiling; Humans; Monocytes; Oligonucleotide Array Sequence Analysis; RNA, Messenger; TNF-Related Apoptosis-Inducing Ligand
Abstract
Dengue fever is an important tropical illness for which there is currently no virus-specific treatment. To shed light on mechanisms involved in the cellular response to dengue virus (DV), we assessed gene expression changes, using Affymetrix GeneChips (HG-U133A), of infected primary human cells and identified changes common to all cells. The common response genes included a set of 23 genes significantly induced upon DV infection of human umbilical vein endothelial cells (HUVECs), dendritic cells (DCs), monocytes, and B cells (analysis of variance, P < 0.05). Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), one of the common response genes, was identified as a key link between type I and type II interferon response genes. We found that DV induces TRAIL expression in immune cells and HUVECs at the mRNA and protein levels. The induction of TRAIL expression by DV was found to be dependent on an intact type I interferon signaling pathway. A significant increase in DV RNA accumulation was observed in anti-TRAIL antibody-treated monocytes, B cells, and HUVECs, and, conversely, a decrease in DV RNA was seen in recombinant TRAIL-treated monocytes. Furthermore, recombinant TRAIL inhibited DV titers in DV-infected DCs by an apoptosis-independent mechanism. These data suggest that TRAIL plays an important role in the antiviral response to DV infection and is a candidate for antiviral interventions against DV.
Rights and Permissions
Citation: J Virol. 2008 Jan;82(1):555-64. Epub 2007 Oct 3. Link to article on publisher's site
Related Resources
Link to Article in PubMed
PubMed ID
17913827
Citation Information
Rajas V. Warke, Katherine J. Martin, Krisanthi Giaya, Sunil K. Shaw, et al.. "TRAIL is a novel antiviral protein against dengue virus" Vol. 82 Iss. 1 (2007) ISSN: 1098-5514 (Electronic)
Available at: http://works.bepress.com/alan_rothman/9/